Capability
AstriVax – Strategic-Technological Analysis
How does AstriVax's plug-and-play thermostable DNA plasmid platform deliver self-amplifying, live-attenuated vaccines?
AstriVax is a Belgian biotechnology venture pioneering a new approach to vaccines. Strategic-technological profile; 33-page sourced DFM PDF report.
Full figures, sources and the complete assessment are in the report — Read the full DFM Analysis →
Part of our Research, Universities & Deep Tech and Defence & Dual-Use Companies coverage →
Original DFM publication · DFM Analysis report · 2025-08-20
AstriVax is a Belgian biotechnology venture pioneering a new approach to vaccines that could reshape Europe’s strategic health security. Founded in 2022 as a spin-off from KU Leuven’s renowned Rega Institute, the company has built a plug-and-play DNA vaccine platform designed to tackle some of the world’s most challenging viral diseases .
AstriVax’s core innovation enables the delivery of live-attenuated vaccines in a radically simpler way: using a thermostable DNA plasmid to launch a self-amplifying vaccine inside the patient .
This analysis answers: How does AstriVax's plug-and-play thermostable DNA plasmid platform deliver self-amplifying, live-attenuated vaccines? What is the clinical and technology readiness of the platform, and how does it fit Europe's strategic health-security autonomy? Which research partners, funders and dual-use markets does the KU Leuven Rega Institute spin-off target? What capability gaps, dependencies and strategic indicators define AstriVax's path to deployment?
Continue with the full evidence
This public thread is the short analytical version. The full DFM Analysis report adds the underlying figures and data, the complete source base, and the full procurement & capital-market assessment behind this summary.
Need the full document as a standalone file? Buy the full report (PDF) — €499
Annual Professional unlocks the complete archive and DFM Intelligence (2,200+ company profiles) — See plans →
Original DFM analysis
AstriVax – Strategic-Technological Analysis
FAQ
What is AstriVax – Strategic-Technological Analysis?
AstriVax’s core innovation enables the delivery of live-attenuated vaccines in a radically simpler way: using a thermostable DNA plasmid to launch a self-amplifying vaccine inside the patient .
Related DFM Platform threads
- Protected Satellite Communications (Operational Priorities) Capability
- Comand AI: AI-Driven Command-and-Control and Operational Planning Capability
- Kongsberg Ferrotech: Subsea Robotics for Europe’s Critical Infrastructure Security Capability
- Microamp Solutions: Enabling Secure 5G and mmWave Technologies for European Defence and Strategic Autonomy Capability
- Sensnet Analytics: European Fiber-Optic Sensing for Critical Infrastructure Security Capability
- Mynaric: Laser Communication Terminals for Secure Space Networks Capability
Explore this category Strategic Autonomy
Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)
See Professional & Institutional Access — plans, group/institutional seats and contact →
Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.
Professional comments
Join the discussion on DFM Analysis.
Read & subscribe on DFM Analysis →